Literature DB >> 31765835

Two for the price of one: Prevalence, demographics and treatment implications of multiple HPV mediated Head and Neck Cancers.

William Strober1, Sachie Shishido2, Burton Wood3, James S Lewis3, Krystle Kuhs3, Robert L Ferris1, Daniel L Faden4.   

Abstract

OBJECTIVES: HPV mediated head and neck squamous cell carcinoma (HPVmHNSCC) is increasing in prevalence in the United States, as are reports of patients with multiple HPVmHNSCCs. The prevalence, demographics, and treatment implications of this emerging clinical entity are poorly understood.
MATERIALS AND METHODS: We performed a multitiered assessment of patients with multiple HPVmHNSCC including: 1. systematic review of the literature, 2. query of the 2017 Surveillance, Epidemiology and End Results (SEER) database and 3. institutional level reporting at two high volume academic centers.
RESULTS: Systematic literature review: 13 articles met inclusion criteria (48 patients with multiple HPVmHNSCC). Pooled prevalence rate of multiple HPVmHNSCC was 2.64%. SEER database: 60(0.95%) patients with HPVmHNSCC had two tumors. Patients with multiple HPVmHNSCC were more likely to be younger and present with a lower T and N stage (p < 0.025 for all). The second identified tumor was more likely to be contralateral, found synchronously, of smaller size, and to occur in the tonsil (p < 0.05 for all). Institutional reporting: 17(1.69%) patients with HPVmHNSCC had two primary tumors. Similar to the SEER database, patients with multiple HPVmHNSCC were more likely to present with a low T stage and tonsil location (p < 0.007 for both).
CONCLUSION: Multiple HPVmHNSCCs occur in a subset of HPVmHNSCC cases with distinct characteristics. Thorough interrogation of all oropharyngeal subsites should be performed as part of the initial workup for HPVmHNSCC, with consideration given to contralateral tonsillectomy at the time of surgical resection for HPV mediated tonsil cancers due to the prevalence of contralateral tonsil primaries.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epidemiology; Head and Neck Cancer; Incidence; Oropharyngeal neoplasms; Papillomavirus infections; SEER program; Second primary neoplasm; Squamous cell carcinoma of head and neck; Systematic review

Mesh:

Year:  2019        PMID: 31765835      PMCID: PMC7017724          DOI: 10.1016/j.oraloncology.2019.104475

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  23 in total

1.  Human papillomavirus and survival of patients with oropharyngeal cancer.

Authors:  K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison
Journal:  N Engl J Med       Date:  2010-06-07       Impact factor: 91.245

2.  Epidemiological Trends of Head and Neck Cancer in the United States: A SEER Population Study.

Authors:  Moustafa Mourad; Thomas Jetmore; Ameya A Jategaonkar; Sami Moubayed; Erin Moshier; Mark L Urken
Journal:  J Oral Maxillofac Surg       Date:  2017-05-22       Impact factor: 1.895

3.  Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence.

Authors:  Jessica H Maxwell; Bhavna Kumar; Felix Y Feng; Francis P Worden; Julia S Lee; Avraham Eisbruch; Gregory T Wolf; Mark E Prince; Jeffrey S Moyer; Theodoros N Teknos; Douglas B Chepeha; Jonathan B McHugh; Susan G Urba; Jay Stoerker; Heather M Walline; David M Kurnit; Kitrina G Cordell; Samantha J Davis; Preston D Ward; Carol R Bradford; Thomas E Carey
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

4.  Long-term analysis of transorally resected p16 + Oropharynx cancer: Outcomes and prognostic factors.

Authors:  Parul Sinha; Bruce H Haughey; Dorina Kallogjeri; Ryan S Jackson
Journal:  Laryngoscope       Date:  2018-08-27       Impact factor: 3.325

5.  Head and neck second primary cancer rates in the human papillomavirus era: A population-based analysis.

Authors:  Dayssy Alexandra Diaz; Isildinha M Reis; Donald T Weed; Nagy Elsayyad; Michael Samuels; Matthew C Abramowitz
Journal:  Head Neck       Date:  2015-08-06       Impact factor: 3.147

6.  Synchronous cancers in patients with head and neck cancer: risks in the era of human papillomavirus-associated oropharyngeal cancer.

Authors:  Kunal S Jain; Andrew G Sikora; Shrujal S Baxi; Luc G T Morris
Journal:  Cancer       Date:  2013-02-19       Impact factor: 6.860

7.  Meta-analysis of second malignant tumors in head and neck cancer: the case for an endoscopic screening protocol.

Authors:  B H Haughey; G A Gates; C L Arfken; J Harvey
Journal:  Ann Otol Rhinol Laryngol       Date:  1992-02       Impact factor: 1.547

8.  Multicentric human papillomavirus-associated head and neck squamous cell carcinoma.

Authors:  Andrew Caley; Mererid Evans; Ned Powell; Vinidh Paleri; Alun Tomkinson; Teresa Guerrero Urbano; Amrita Jay; Max Robinson; Selvam Thavaraj
Journal:  Head Neck       Date:  2014-03-20       Impact factor: 3.147

9.  Human papillomavirus and the landscape of secondary genetic alterations in oral cancers.

Authors:  Maura L Gillison; Keiko Akagi; David E Symer; Weihong Xiao; Bo Jiang; Robert K L Pickard; Jingfeng Li; Benjamin J Swanson; Amit D Agrawal; Mark Zucker; Birgit Stache-Crain; Anne-Katrin Emde; Heather M Geiger; Nicolas Robine; Kevin R Coombes
Journal:  Genome Res       Date:  2018-12-18       Impact factor: 9.043

10.  HPV status and second primary tumours in oropharyngeal squamous cell carcinoma.

Authors:  Caroline C Xu; Vincent L Biron; Lakshmi Puttagunta; Hadi Seikaly
Journal:  J Otolaryngol Head Neck Surg       Date:  2013-05-29
View more
  7 in total

1.  HPV+ oropharyngeal squamous cell carcinomas from patients with two tumors display synchrony of viral genomes yet discordant mutational profiles and signatures.

Authors:  Daniel L Faden; Adam Langenbucher; Krystle Kuhs; James S Lewis; Lisa Mirabello; Meredith Yeager; Joseph F Boland; Sara Bass; Mia Steinberg; Michael Cullen; Michael S Lawrence; Robert L Ferris
Journal:  Carcinogenesis       Date:  2021-02-11       Impact factor: 4.944

2.  Development of second primary malignancies after transoral surgery in human papilloma virus-positive oropharyngeal squamous cell carcinoma.

Authors:  Katelyn Stepan; Ethan Craig; Scott Andrew Skillington; Brian C Deutsch; Stephanie Chen; Nneoma S Wamkpah; Craig A Bollig; Dorina Kallogjeri; Wade L Thorstad; Sidharth V Puram; Patrik Pipkorn; Ryan S Jackson
Journal:  Head Neck       Date:  2022-02-17       Impact factor: 3.821

3.  Prevalence of Transcriptionally Active HPV Infection in Tumor-Free Oropharyngeal Tissue of OPSCC-Patients.

Authors:  Vittoria Guarda; Lea Schroeder; Michael Pawlita; Kristian Ikenberg; Niels J Rupp; Wolfram Jochum; Sandro J Stoeckli; Dana Holzinger; Martina A Broglie
Journal:  Front Oncol       Date:  2022-04-22       Impact factor: 5.738

4.  Prospective assessment of multiple HPV-positive oropharyngeal squamous cell carcinomas.

Authors:  Daniel L Faden; Connor J O'Boyle; Derrick T Lin; Daniel G Deschler; Kevin S Emerick; Mark A Varvares; William C Faquin; Peter M Sadow; Jeremy D Richmon
Journal:  Oral Oncol       Date:  2021-02-15       Impact factor: 5.972

5.  Single-cell transcriptomic profiling for inferring tumor origin and mechanisms of therapeutic resistance.

Authors:  Michael S Lawrence; Daniel L Faden; Maoxuan Lin; Moshe Sade-Feldman; Lori Wirth
Journal:  NPJ Precis Oncol       Date:  2022-10-10

Review 6.  Human Papillomavirus and Squamous Cell Carcinoma of Unknown Primary in the Head and Neck Region: A Comprehensive Review on Clinical Implications.

Authors:  Mikkel Hjordt Holm Larsen; Hani Ibrahim Channir; Christian von Buchwald
Journal:  Viruses       Date:  2021-07-02       Impact factor: 5.048

Review 7.  Current Status of Human Papillomavirus-Related Head and Neck Cancer: From Viral Genome to Patient Care.

Authors:  Haoru Dong; Xinhua Shu; Qiang Xu; Chen Zhu; Andreas M Kaufmann; Zhi-Ming Zheng; Andreas E Albers; Xu Qian
Journal:  Virol Sin       Date:  2021-06-21       Impact factor: 4.327

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.